Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

The Leedham Lab in Nuffield Department of Medicine (NDM) has been awarded over £2M from Cancer Research UK to develop a new tool that could help guide how bowel cancer patients are treated in the future.

Bowel cancer

Bowel cancer is the fourth most common cancer in the UK with nearly 43,000 people diagnosed every year. 

“Our understanding of the biology of bowel cancer is really advancing very rapidly, and this has been helped by the ability to examine samples of tumours with a wide range of molecular tools,” explains Simon Leedham, Professor of Molecular and Population Genetics from the University of Oxford, and Honorary Consultant at the John Radcliffe Hospital.

Funding from Cancer Research UK has enabled the Leedham Lab NDM at Oxford University to develop a brand-new molecular tool, which could lead to a step change in how to choose the best treatment for each patient at the right time.

Read the full story on the Oxford Cancer website